Every 10-Q that Kura Oncology, Inc. (KURA) has filed with the SEC in the last 24 months is listed below, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A 10-Q covers the quarterly report filed between annual reports, so if you follow KURA and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full KURA filings page.
Kura Oncology, Inc. is a commercial-stage biopharmaceutical company focused on precision oncology, now generating its first product revenue from KOMZIFTI (ziftomenib) for relapsed or refractory NPM1-mutated AML in the United States. For the six months ended June 30, 2026, total revenue was $39.1 million, including $14.9 million in KOMZIFTI net product revenue and $24.3 million in collaboration revenue from its global ziftomenib partnership with Kyowa Kirin.
Research and development expenses were $127.2 million, reflecting ongoing ziftomenib combination trials and darlifarnib Phase 1 work, while selling, general and administrative expenses rose to $63.3 million as commercial and corporate infrastructure expanded. Kura reported a net loss of $141.7 million, or $1.60 per share, compared with $123.6 million a year earlier, and used $148.4 million of cash in operating activities in the first half.
Liquidity remains significant, with $70.2 million in cash and cash equivalents and $448.8 million in short-term investments, totaling $519.0 million at June 30, 2026, plus a term loan facility. The company states it believes this balance, together with anticipated $180.0 million in additional Kyowa payments, will fund its current plan into late 2027 and through first topline KOMET-017 results anticipated in 2028.
Kura Oncology reported first-quarter 2026 results showing its transition into a commercial-stage company. Total revenue reached $18.3 million, including $5.8 million in net product revenue from KOMZIFTI, its newly launched AML drug, and $12.5 million of collaboration revenue from the Kyowa Kirin partnership.
The company’s operating expenses rose with commercialization and late-stage development, driving a net loss of $73.3 million, or $0.83 per share. Research and development spending was $65.3 million and selling, general and administrative expenses were $31.6 million, reflecting expanding clinical programs and commercial infrastructure.
Kura ended March 31, 2026 with $580.8 million in cash, cash equivalents and short-term investments and contract liabilities of $464.4 million related mainly to the Kyowa Kirin agreement. Management believes this cash, combined with expected partnership payments, can fund its operating plan into the fourth quarter of 2027 and through initial Phase 3 ziftomenib readouts anticipated in 2028.
Kura Oncology (KURA) reported Q3 2025 results with collaboration revenue of $20.8 million, driven by its Kyowa Kirin partnership, and a net loss of $74.1 million ($0.85 per share). Operating expenses rose to $100.7 million on higher R&D ($67.9 million) and G&A ($32.8 million).
Liquidity remained strong with $549.7 million in cash, cash equivalents and short-term investments as of September 30, 2025. Contract liabilities tied to deferred collaboration revenue totaled $317.6 million, reflecting services to be delivered; receivables from collaborators were $35.9 million. Shares outstanding were 87.0 million as of October 31, 2025.
The company’s NDA for ziftomenib in relapsed/refractory NPM1-mutated AML was accepted with Priority Review and a PDUFA target action date of November 30, 2025. Kura also amended its term loan on October 25, 2025 to extend interest-only payments, with a further extension possible upon an approval milestone.